Donald Morel: They’re actually contract manufacturing lines for 2 products that we expect our customers to receive approval. One should be in the second quarter and one should be late in the third. 
Donald Morel: A little bit of both. I mean, it's a mix depending on a specific customer, but there are cost offsets through the tooling and some of the assembly equipment. It's customer-specific. 
Donald Morel: I think there is a whole host of factors. Part of it is timing, so we've got a number of large med device customers whose fiscal year ends September 30. So clearly what they were doing was managing down inventories in our third quarter, and what we received was several large bonus orders into the backlog to begin their new fiscal year, which started October 1. But we’ve also seen general demand increasing in areas like diabetes, which we think is very positive, as well as some of the exports that we do out of Europe into the North Africa and Middle Eastern and Eastern European countries, so, strong growth there. A little bit of it is an extension of lead times. When our factories get to the point where we’re running them now, which is kind of that mid-80s utilization level, you will see lead times extend a little bit. So it's so far manageable. 
Donald Morel: Thank you very much for your time this morning. And this concludes our call for today. If you have any further questions please do not hesitate to call Mike, Bill or myself. Thank you very much. 
